SHANGHAI KAIBAO's wholly-owned subsidiary has obtained a drug registration certificate
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, SHANGHAI KAIBAO announced that its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd. (referred to as "subsidiary") recently received the Drug Registration Certificate for Doxofylline Tablets issued by the National Medical Products Administration. Doxofylline Tablets are suitable for bronchial asthma, asthmatic chronic bronchitis, and other respiratory difficulties caused by bronchospasm
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments